Research & Reviews: Drug Delivery

Role of Blood Brain Barrier and Advancements in Drug Delivery to the Brain

Karnchanok Tamprasit*

Department of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand

Commentary

Received: 28-Feb-2024, Manuscript No. DD-24-131135; **Editor assigned:** 01-Mar-2024, Pre QC No. DD-24-131135(PQ); **Reviewed:** 15-Mar-2024, QC No. DD-24-131135; **Revised:** 22-Mar-2024, Manuscript No. DD-24-131135(R); **Published:** 29-Mar-2024, DOI:10.4172/resrevdrugdeliv.8.1.004

***For Correspondence:**
Karnchanok Tamprasit, Department of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand
E-mail: kkrnnk@gmail.com

Citation: Tamprasit K. Role of Blood Brain Barrier and Advancements in Drug Delivery to the Brain. Res Rev Drug Deliv. 2024;8:004.

ABOUT THE STUDY

The Blood-Brain Barrier (BBB) poses a formidable challenge in delivering therapeutic agents to the brain. Its selective permeability restricts the passage of drugs, making the treatment of neurological disorders particularly challenging. However, recent advancements in drug delivery technologies have paved the way for innovative strategies to bypass or overcome the BBB and target drugs to the brain. This article explores the various approaches and advancements in drug delivery to the brain, with a focus on enhancing therapeutic efficacy and addressing neurological disorders.

Understanding the Blood-Brain Barrier (BBB)

The BBB is a highly selective membrane composed of endothelial cells that line the brain's capillaries. Its tight junctions prevent the passage of most molecules, including therapeutic agents, into the brain parenchyma. While essential for maintaining brain homeostasis and protecting against neurotoxic substances, the BBB presents a significant hurdle for drug delivery to the Central Nervous System (CNS).

Strategies to overcome the BBB

Nanoparticles offer a promising platform for drug delivery to the brain. Their small size allows them to bypass the BBB through various mechanisms, including receptor-mediated transcytosis, adsorptive-mediated transcytosis, and passive diffusion.

Surface modifications with targeting ligands enable specific binding to BBB receptors, facilitating drug transport into the brain parenchyma. Focused Ultrasound (FUS) combined with microbubble contrast agents can transiently disrupt the BBB, allowing for targeted drug delivery to specific brain regions. This non-invasive approach offers precise control over drug delivery while minimizing off-target effects. FUS-mediated BBB opening has shown promise in preclinical and clinical studies for the treatment of neurological disorders such as Alzheimer's disease and brain tumors. The intranasal route provides a direct pathway for drugs to reach the brain *via* the olfactory and trigeminal nerve pathways, bypassing the BBB. Intranasal delivery offers advantages such as rapid absorption, avoidance of first-pass metabolism, and reduced systemic side effects. It has been explored for the delivery of various therapeutic agents, including peptides, proteins, and small molecules, for the treatment of neurological disorders.

Advancements in drug formulations

Lipid-based formulations, such as liposomes and lipid nanoparticles, can encapsulate hydrophobic drugs and improve their solubility, stability, and bioavailability. These formulations can be engineered to target specific brain regions and facilitate drug transport across the BBB. Lipid-based carriers have shown promise in delivering drugs for the treatment of neurodegenerative diseases and brain tumors. Polymeric nanocarriers, including polymeric micelles, dendrimers, and polymer-drug conjugates, offer versatility in drug delivery to the brain. These carriers can be surface-modified with targeting ligands or responsive moieties to enhance BBB penetration and brain accumulation. Polymeric nanocarriers have been investigated for delivering a wide range of therapeutics, including chemotherapeutic agents, antioxidants, and neuroprotective drugs.

Clinical applications and future perspectives

While significant progress has been made in drug delivery to the brain, challenges such as safety, scalability, and clinical translation remain. Continued research efforts are focused on optimizing delivery systems, improving BBB penetration, and advancing preclinical and clinical validation. The development of personalized medicine approaches and combination therapies holds promise for addressing the complexity of neurological disorders and improving patient outcomes. Drug delivery to the brain represents a frontier in neuroscience and pharmacology, with the potential to revolutionize the treatment of neurological disorders. By leveraging innovative strategies and advancements in drug delivery technologies, researchers are overcoming the barriers imposed by the BBB and delivering therapeutic agents to the brain with increased precision and efficacy. With continued interdisciplinary collaboration and translational research, the future holds promise for transformative therapies that target the underlying mechanisms of neurological diseases and improve the quality of life for patients worldwide.